Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM

Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine, Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low‐dens...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsui, Hoyee, Han, Su Ji, van Rooij, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422066/
https://www.ncbi.nlm.nih.gov/pubmed/34411432
http://dx.doi.org/10.15252/emmm.202114789
_version_ 1783749211333853184
author Tsui, Hoyee
Han, Su Ji
van Rooij, Eva
author_facet Tsui, Hoyee
Han, Su Ji
van Rooij, Eva
author_sort Tsui, Hoyee
collection PubMed
description Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine, Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low‐density lipoproteins (oxLDL) and ACM disease penetrance, which contributes to fibro‐fatty cardiac remodeling via the oxLDL/CD36/PPARγ axis. These data identify oxidized low‐density lipoproteins as a risk factor for ACM and uncover a novel therapeutic intervention option to block disease pathogenesis.
format Online
Article
Text
id pubmed-8422066
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84220662021-09-10 Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM Tsui, Hoyee Han, Su Ji van Rooij, Eva EMBO Mol Med News & Views Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine, Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low‐density lipoproteins (oxLDL) and ACM disease penetrance, which contributes to fibro‐fatty cardiac remodeling via the oxLDL/CD36/PPARγ axis. These data identify oxidized low‐density lipoproteins as a risk factor for ACM and uncover a novel therapeutic intervention option to block disease pathogenesis. John Wiley and Sons Inc. 2021-08-19 2021-09-07 /pmc/articles/PMC8422066/ /pubmed/34411432 http://dx.doi.org/10.15252/emmm.202114789 Text en © 2021 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Tsui, Hoyee
Han, Su Ji
van Rooij, Eva
Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_full Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_fullStr Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_full_unstemmed Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_short Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_sort oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for acm
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422066/
https://www.ncbi.nlm.nih.gov/pubmed/34411432
http://dx.doi.org/10.15252/emmm.202114789
work_keys_str_mv AT tsuihoyee oxidizedlowdensitylipoproteinsasanovelriskfactorandtherapeutictargetforacm
AT hansuji oxidizedlowdensitylipoproteinsasanovelriskfactorandtherapeutictargetforacm
AT vanrooijeva oxidizedlowdensitylipoproteinsasanovelriskfactorandtherapeutictargetforacm

Ejemplares similares